Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, José Antônio Sanches et al.|The Lancet|2017Cited by 580
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJeremy S. Abramson, Andrew M. Evens, Tatyana Feldman et al.|Annals of Oncology|2014Cited by 138
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphomaJoanna Zurko, Alex F. Herrera, Jeremy Ramdial et al.|Haematologica|2022Cited by 73
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C. Thompson, Anthony R. Mato, Rosemary Harrup et al.|Blood Advances|2022Cited by 57